Literature DB >> 21205751

Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?

Nitin Verma, Sandra M Swain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21205751     DOI： 10.1200/JCO.2010.32.9060

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

Authors:  Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; André Robidoux; James N Atkins; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

2.  A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Authors:  Satoru Miura; Makoto Maemondo; Akira Iwashima; Toshiyuki Harada; Shunichi Sugawara; Kunihiko Kobayashi; Akira Inoue; Taku Nakagawa; Yuichi Takiguchi; Hiroshi Watanabe; Takashi Ishida; Masaki Terada; Hiroshi Kagamu; Akihiko Gemma; Hirohisa Yoshizawa
Journal:  Invest New Drugs       Date:  2017-02-01       Impact factor: 3.850

3.  Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Authors:  Ranjana H Advani; Fangxin Hong; Sandra J Horning; Brad S Kahl; Judith Manola; Lode J Swinnen; Thomas M Habermann; Kristen Ganjoo
Journal:  Leuk Lymphoma       Date:  2011-12-05

4.  Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Authors:  Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2011-05-12

5.  A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Michael LeBlanc; Brent Farnsworth; Maria Iannone; Martha J Glenn; Richard I Fisher; Thomas P Miller
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

Review 6.  Bevacizumab: a review of its use in advanced cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

7.  Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.

Authors:  Haruka Chino; Yosuke Amano; Yasuhiro Yamauchi; Jun Matsuda; Norihiko Takeda; Goh Tanaka; Daiya Takai; Takahide Nagase
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 8.  Cardiovascular complications of metastatic colorectal cancer treatment.

Authors:  Kalliopi Keramida; Georgios Charalampopoulos; Dimitrios Filippiadis; Elias Tsougos; Dimitrios Farmakis
Journal:  J Gastrointest Oncol       Date:  2019-08

9.  Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis.

Authors:  Julia Kravchenko; Mark Berry; Konstantin Arbeev; H Kim Lyerly; Anatoly Yashin; Igor Akushevich
Journal:  Lung Cancer       Date:  2015-01-17       Impact factor: 5.705

Review 10.  Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab.

Authors:  Alexandra Gherman; Călin Căinap; Anne-Marie Constantin; Sînziana Cetean; Simona Sorana Căinap
Journal:  Clujul Med       Date:  2017-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.